Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ADCT – Adc Therapeutics SA

ADCT — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

4.63

Margin Of Safety %

Put/Call OI Ratio

0.05

EPS Next Q Diff

-0.15

EPS Last/This Y

0.32

EPS This/Next Y

0.16

Price

3.74

Target Price

8.2

Analyst Recom

1

Performance Q

4.49

Upside

-1,229.0%

Beta

1.98

Ticker: ADCT



16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09ADCT4.230.070.002669
2026-03-10ADCT4.80.070.002661
2026-03-11ADCT4.880.060.002750
2026-03-12ADCT4.350.060.272752
2026-03-13ADCT4.350.060.142752
2026-03-17ADCT4.110.060.003189
2026-03-18ADCT4.010.060.003070
2026-03-20ADCT3.880.060.133212
2026-03-25ADCT3.970.040.002794
2026-03-26ADCT3.960.040.002815
2026-03-27ADCT3.70.040.002873
2026-03-30ADCT3.650.040.042876
2026-03-31ADCT3.740.052.002958
2026-04-01ADCT3.80.050.002950
2026-04-06ADCT3.670.050.002986
2026-04-07ADCT3.740.050.003027
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09ADCT4.23- - -1.41
2026-03-10ADCT4.79- - -1.41
2026-03-11ADCT4.89- - -1.41
2026-03-12ADCT4.34- - -0.81
2026-03-13ADCT4.13- - -0.81
2026-03-17ADCT4.10- - -0.81
2026-03-18ADCT4.01- - -0.81
2026-03-19ADCT4.02- - -0.81
2026-03-20ADCT3.87- - -0.81
2026-03-23ADCT4.05- - -0.81
2026-03-24ADCT3.94- - -0.81
2026-03-25ADCT3.98- - -0.81
2026-03-26ADCT3.94- - -0.81
2026-03-27ADCT3.71- - -0.81
2026-03-30ADCT3.65- - -0.80
2026-03-31ADCT3.74- - -0.80
2026-04-01ADCT3.80- - -0.80
2026-04-02ADCT3.80- - -0.80
2026-04-06ADCT3.68- - -0.80
2026-04-07ADCT3.74- - -0.80
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09ADCT0.003.634.83
2026-03-10ADCT0.003.634.83
2026-03-11ADCT0.003.634.54
2026-03-12ADCT0.003.634.54
2026-03-13ADCT0.003.634.43
2026-03-18ADCT0.003.614.43
2026-03-19ADCT0.003.614.43
2026-03-20ADCT0.003.614.43
2026-03-23ADCT0.003.614.43
2026-03-24ADCT0.003.614.43
2026-03-25ADCT0.003.614.63
2026-03-26ADCT0.003.614.63
2026-03-27ADCT0.003.614.63
2026-03-30ADCT0.003.604.63
2026-03-31ADCT0.003.604.63
2026-04-01ADCT0.003.604.63
2026-04-02ADCT0.003.604.63
2026-04-06ADCT-14.623.604.63
2026-04-07ADCT-14.623.604.63
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

-0.04

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

-14.62

Institutional Transactions

3.6

Beta

1.98

Average Sales Estimate Current Quarter

19

Average Sales Estimate Next Quarter

19

Fair Value

Quality Score

72

Growth Score

29

Sentiment Score

68

Actual DrawDown %

88.3

Max Drawdown 5-Year %

-98.5

Target Price

8.2

P/E

Forward P/E

PEG

P/S

5.81

P/B

P/Free Cash Flow

EPS

-1.2

Average EPS Est. Cur. Y​

-0.8

EPS Next Y. (Est.)

-0.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-175.31

Relative Volume

0.98

Return on Equity vs Sector %

49.3

Return on Equity vs Industry %

65.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.28

EBIT Estimation

◆ ADCT Healthcare
$3.72
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
7/20
Pullback
22/25
Volume
7/15
Valuation
10/20
TP/AR
2/10
Options
6/10
RSI
42.3
Range 1M
17.4%
Sup Dist
3%
🚀
Momentum Growth
Ride accelerating trends
N/A
45 /100
WEAK
Momentum
4/25
Growth
24/30
Estimates
2/20
Inst/Vol
7/15
Options
8/10
EPS Yr
28.6%
EPS NY
20.3%
52W%
68.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +120.4% upside
Quality
7/30
Valuation
16/30
Growth
19/25
Stability
7/10
LT Trend
1/5
Upside
+120.4%
Quality
72
Click a card to see score breakdown Full Analysis →
ADC Therapeutics SA
Sector: Healthcare
Industry: Biotechnology
Employees: 188
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ADCT

Latest News

—
Caricamento notizie per ADCT…
stock quote shares ADCT – Adc Therapeutics SA Stock Price stock today
news today ADCT – Adc Therapeutics SA stock forecast ,stock prediction 2023 2024 2025
marketwatch ADCT – Adc Therapeutics SA yahoo finance google finance
stock history ADCT – Adc Therapeutics SA invest stock market
stock prices ADCT premarket after hours
ticker ADCT fair value insiders trading